• In search for new monoclonal antibodies, the authors used an antigenic polypeptide, which yielded numbers of new binders that may lead to production of anti-CD20 antibodies, with improved diagnostic or clinical attributes. (pubchase.com)
  • Monoclonal antibodies target the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. (medscape.com)
  • Arlen M, Arlen P, Tsang A, Wang X, Gupta R. The Therapeutic Value of Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins. (jcancer.org)
  • Monoclonal antibodies developed against immunogenic proteins (Tumor Specific Antigens/TSA's) that are expressed in human cancers, display a unique behavioral pattern. (jcancer.org)
  • It is required by FDA that the potential effects of tumor control and toxicity be defined using the naked antibodies produced under GMP conditions, In those situations where patients with recurrent malignancies are to be studied we have come to realize that a number of factors can influence the response to monoclonal therapy. (jcancer.org)
  • As a result, we must down-regulate their numbers using anti-CD20 monoclonal antibodies to treat such patients (Tab. (elis.sk)
  • Traditional polyclonal and monoclonal antibodies are the product of normal B cell development and genetic recombination. (cellsignal.cn)
  • While polyclonal antibodies are secreted by many different B cell clones and recognize multiple antigenic epitopes, monoclonals originate from a single B cell clone and are specific for just one epitope. (cellsignal.cn)
  • Recombinant antibodies are monoclonal, but their production involves in vitro genetic manipulation. (cellsignal.cn)
  • In contrast, hybridoma-based systems for producing monoclonal antibodies are subject to genetic drift and instability, increasing the potential for lot-to-lot variability or loss of antibody expression. (cellsignal.cn)
  • Where polyclonal antibodies are purified directly from the serum of the immunized host, and monoclonals are purified from either hybridoma-derived tissue culture supernatant or ascites, recombinant antibodies are instead purified from the tissue culture supernatants of transfected host cell lines. (cellsignal.cn)
  • T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
  • The disease is generally categorized as warm or cold, depending on the thermal reactivity of the autoantibodies Autoantibodies Antibodies that react with self-antigens (autoantigens) of the organism that produced them. (lecturio.com)
  • In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. (justia.com)
  • Glennie MJ, French RR, Cragg MS, Taylor RP: Mechanisms of killing by anti-CD20 monoclonal antibodies. (exbio.cz)
  • Moreover this efficacy is frequently abrogated by a second site mutation that reduces TKI affinity for the EGFR kinase website16 17 1.3 There are numerous therapeutic monoclonal antibodies that target extracellular epitopes of cell surface proteins whose expression is associated with a pathologic state. (biobender.com)
  • Hyodeoxycholic acid In some cases these antibodies appear to function primarily by eliciting an immune response specific for the cells that communicate the targeted cell surface antigen. (biobender.com)
  • 1.3 Inhibitors of ligand binding Various other monoclonal antibodies bind for an RTK and stop agonist binding towards the RTK and agonist stimulation of RTK signaling. (biobender.com)
  • Rituximab is an anti-CD20 monoclonal antibody indicated for adults with pemphigus vulgaris in combination with short-term corticosteroid therapy. (medscape.com)
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. (drugs.com)
  • Rituximab is a monoclonal antibody targeted against the B-cell surface antigen CD20. (asn-online.org)
  • Rituximab (RTX) is a CD20‑targeting antibody that is the standard‑of‑care for patients with non‑Hodgkin Lymphoma (NHL) cases. (spandidos-publications.com)
  • This strategy includes the monoclonal anti-CD20 antibody, rituximab (RTX), alone or in combination with chemotherapy for patients who have advanced-stage disease. (spandidos-publications.com)
  • Rituximab is a monoclonal antibody that binds to the CD20 antigen, causing antibody-mediated cytolysis. (medscape.com)
  • 5 Combining rituximab, a monoclonal antibody targeting the CD20 antigen on B cells, with standard chemotherapy has improved NHL treatment outcomes. (haematologica.org)
  • Rituximab is an immunoglobulin G1 (IgG1) kappa monoclonal antibody composed of a murine (mouse) variable region (Fab portion) that is fused onto a human constant region (Fc portion). (dermnetnz.org)
  • Retreatment may or may not prove successful as lymphomas can lose CD20 expression and, with that, susceptibility to rituximab. (dermnetnz.org)
  • A monoclonal antibody called rituximab can bind to the B lymphocyte's Clusters of Differentiation (CD) 20 antigen and eliminate B lymphocytes from the bloodstream. (ijpsonline.com)
  • Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. (edu.pl)
  • Rituximab is a chimeric monoclonal antibody directed against CD20 antigen. (pbkom.eu)
  • Using the monoclonal antibody rituximab as a model therapeutic protein, a uniform Gal2GlcNAc2Man3GlcNAc2 (A2G2) glycoform without α-1,6-fucose, plant-specific α-1,3-fucose or β-1,2-xylose residues was produced. (umd.edu)
  • Rituximab (RTX) is a chimeric anti - CD20 monoclonal antibody inducing transient B lymphocytes depletion that was shown to be useful and safe in the majority of HCV MC patients, leading also to improvement of cirrhotic syndrome. (biomedcentral.com)
  • Rituxan (rituximab) is a monoclonal antibody indicated for the treatment of several B-cell-mediated conditions, including non-Hodgkin's lymphoma, leukemia, and rheumatoid arthritis. (managedhealthcareexecutive.com)
  • Rituximab is a monoclonal antibody that binds to an antigen called CD20 on the surface of both healthy and cancerous B cells, which marks them for destruction by the immune system. (cancertodaymag.org)
  • It was the aim of this paper to identify prognostic factors in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas, treated by radioimmunotherapy (RIT) with radioiodinated human/murine chimeric anti-CD20 monoclonal antibody rituximab ( 131 I-rituximab). (karger.com)
  • For example the monoclonal antibody rituximab (Rituxan? (biobender.com)
  • Adoptive T-cell therapy with anti-CD19 chimeric antigen receptor (CAR)-expressing T cells is a new approach for treating advanced B-cell malignancies. (ashpublications.org)
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • Currently many stem or progenitor cell therapies including T cell receptor (TCR) or chimeric antigen receptor (CAR) focusing on epitopes indicated on malignant cells are under development for medical translation (17C20). (bioskinrevive.com)
  • Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. (wikipedia.org)
  • Murine monoclonal antibody targeted against CD-20 antigen located on mature B lymphocytes but not on normal stem cells or progenitor cells. (drugfuture.com)
  • We used T cells that were retrovirally transduced with this CAR to treat mice bearing a syngeneic lymphoma that naturally expressed the self-antigen murine CD19. (ashpublications.org)
  • CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. (thermofisher.com)
  • After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. (thermofisher.com)
  • The antibody LT20 reacts with an extracellular epitope of CD20 (Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes. (exbio.cz)
  • Petrie RJ, Deans JP: Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. (exbio.cz)
  • CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. (thermofisher.com)
  • Chronic lymphocytic leukemia (CLL) is a monoclonal disorder characterized by a progressive proliferation and accumulation of mature yet functionally incompetent lymphocytes. (medscape.com)
  • Given by intravenous injection, it is very effective at destroying normal and malignant B lymphocytes that are carrying the CD20 antigen. (dermnetnz.org)
  • The Fab portion binds to the CD20 antigen on the surface of pre-B and mature B lymphocytes. (dermnetnz.org)
  • CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). (exbio.cz)
  • Hultin LE, Hausner MA, Hultin PM, Giorgi JV: CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. (exbio.cz)
  • Ublituximab is a novel, third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen found on B lymphocytes. (tgtherapeutics.com)
  • TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. (tgtherapeutics.com)
  • Mouse monoclonal to CD22.K22 reacts with CD22, a 140 kDa B-cell specific molecule, expressed in the cytoplasm of all B lymphocytes and on the cell surface of only mature B cells. (bioskinrevive.com)
  • Interestingly, the number of CD80 + pDC positively correlates with the presence of IL-10-producing regulatory type 1 cells (Tr1), an important cell type for maintaining peripheral tolerance to self-antigens. (hindawi.com)
  • Most CARs that are being evaluated in current clinical and preclinical studies recognize self-antigens that are expressed by normal tissues as well as malignant cells. (ashpublications.org)
  • In certain lymphomas, the immunoglobulin antigen that the lymphoid cell is supposed to be producing becomes mutated, and hence a potential target for vaccines. (oncolink.org)
  • However, inclusion of CD20 ABC to routine panel does not seem plausible but may be done for difficult diagnostic cases or where anti-CD20 therapy is planned. (cusabio.com)
  • Limiting the antibody-induced induction of immunosuppressive reactive oxygen species may improve the anti-leukemic efficacy of anti-CD20 therapy in chronic lymphocytic leukemia. (cusabio.com)
  • We believe Ublituximab, a next generation anti-CD20 therapy will strengthen our presence in oncology and auto-immune areas and look forward to working with TG Therapeutics in developing Ublituximab in South Korea and Southeast Asia . (tgtherapeutics.com)
  • Ublituximab has been granted orphan status in Europe and in the USA for B-cell Chronic Lymphocytic Leukemia, and is currently being evaluated in a Phase I/II clinical trial in patients with non-Hodgkin's lymphoma relapsed or refractory to prior anti-CD20 therapy. (tgtherapeutics.com)
  • Description: The 2H7 monoclonal antibody reacts with human CD20, a 33-36 kDa transmembrane protein. (thermofisher.com)
  • Mouse monoclonal to CD20.COC20 reacts with human CD20 (B1), 37/35 kDa protien, which is expressed on pre-B cells and mature B cells but not on plasma cells. (researchhunt.com)
  • Anti-CD19-CAR-transduced T cells had superior antilymphoma efficacy compared with the anti-CD19 monoclonal antibody from which the anti-CD19 CAR was derived. (ashpublications.org)
  • 12 , 13 Clinical trials in which patients with advanced B-cell malignancies receive T cells expressing anti-CD19 CARs are in early stages, and it is not known whether adoptive transfer of T cells targeting this self-antigen will be an effective therapy for B-cell malignancies. (ashpublications.org)
  • The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
  • In contrast with CD10, CD19 and CD20 antigen, CD22 antigen is still present on lymphoplasmacytoid cells but is dininished on the fully mature plasma cells. (bioskinrevive.com)
  • CD20 is a B-cell-specific antigen expressed on malignant FL cells. (spandidos-publications.com)
  • Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
  • CD22 antigen is present in the most B-cell leukemias and lymphomas but not T-cell leukemias. (bioskinrevive.com)
  • Genentech) is effective against many B-cell lymphomas by focusing on the CD20 antigen which is definitely overexpressed by these tumor cells18-23. (biobender.com)
  • One insight is the identification of tumor antigens (small proteins recognized as "foreign" by the immune system) that stimulate the T-cells of the immune system. (oncolink.org)
  • Monoclonals developed from these tumor antigens are in the initial phases of investigation with regard to their specificity and antitumor activity. (jcancer.org)
  • When compared with the innovator product Rituxan®, the plant-made remodeled afucosylated antibody showed similar binding affinity to the CD20 antigen but significantly enhanced cell cytotoxicity in vitro. (umd.edu)
  • Rituxan exerts its effect by targeting and binding to the CD20 antigen on the surface of B cells, resulting in B-cell depletion. (managedhealthcareexecutive.com)
  • The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. (exbio.cz)
  • Technically, due to a short extra membrane domain, the recombinant CD20 protein is a difficult antigen to raise immune responses. (pubchase.com)
  • Regardless of whether an antibody is polyclonal, monoclonal or recombinant, it must always be properly validated in the intended application prior to experimental use. (cellsignal.cn)
  • CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment. (thermofisher.com)
  • As such, targeting CD20 is a viable therapeutic strategy and plays a central role in the treatment of FL. (spandidos-publications.com)
  • BEXXAR pairs the targeting ability of a monoclonal antibody (Tositumomab) and the therapeutic potential of radiation (Iodine-131). (salesandmarketingnetwork.com)
  • Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. (drugs.com)
  • Recent clinical evidence suggests that high serum levels of the tumor‑produced mucin 16 (MUC16) and cancer antigen 125 (CA125) have a negative impact on the effectiveness of RTX clinical activity in up to 40% of patients with follicular lymphoma. (spandidos-publications.com)
  • The antibody 3B4C10 with a balanced Kon and Koff may be applicable in the construction of affinity columns or beads for isolation and purification of CD20-positive cells and cancer stem cells. (pubchase.com)
  • CD20 is expressed by developing B cells as well as mature B cells but not plasma cells. (thermofisher.com)
  • CD20 has been detected at low levels on a small subset of mature T cells. (thermofisher.com)
  • CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation. (thermofisher.com)
  • These tumor specific antigens are the result of mutations that cancer cells undergo, and in many cases that involve viral carcinogens, viral antigens. (oncolink.org)
  • Rather than attempting to determine the exact antigen on the cancer cells themselves, an alternative approach has been to isolate and to study the immunogobulins that our bodies have produced in recognition of these foreign antigens. (oncolink.org)
  • Recently, cells called antigen presenting cells (APCs) were discovered to play a pivotal role in the immune response. (oncolink.org)
  • These cells, such as dendritic cells, process foreign antigens and then present them to T-cells, causing their intense activation. (oncolink.org)
  • In fact, immature dendritic cells can actually cause the suppression of responses to antigen. (oncolink.org)
  • Hence, it would help create more T-cells that react to the antigen presented. (oncolink.org)
  • As noted above, a more vigorous dendritic cell presentation of antigens could trigger the immune response by T-cells. (oncolink.org)
  • Co-stimulatory molecules are presenting along with the antigen by APCs to induce an aggressive response by the T-cells. (oncolink.org)
  • The mechanisms of action by which RTX kills FL cells include complement-dependent cytotoxicity (CDC) ( 3 ), antibody-dependent cellular cytotoxicity (ADCC) ( 4 , 5 )-herein referred to as 'effector function' mechanisms-as well as CD20 signaling effects ( 6 ). (spandidos-publications.com)
  • The CD20 antigen is not found on stem cells or early pro- B cells so these can regenerate the B lymphocyte population. (dermnetnz.org)
  • Plasma cells are B cells that do not usually express the CD20 antigen, so they mostly survive. (dermnetnz.org)
  • DC are professional antigen-presenting cells with the unique capacity to polarize the differentiation of T cells, thereby regulating the balance between inflammation and tolerance [ 12 ]. (hindawi.com)
  • Combined, these agents form a radiolabeled monoclonal antibody regimen that is able to bind to the target antigen CD20 found on B cells, including normal B-cells and those that become cancerous in NHL, thereby delivering the dose of radiation. (salesandmarketingnetwork.com)
  • Adoptive T-cell therapy with T cells expressing chimeric antigen receptors (CARs) is an active area of cancer research. (ashpublications.org)
  • It was shown that molecular mimicry between the EBNA-1 antigen of the Epstein-Barr virus and the GlialCAM molecule of glial cells forms the basis that triggers the entire pathological process. (elis.sk)
  • 1 T cells are engineered to express CARs through viral vectors, enabling them to recognize specific target antigens. (bdbiosciences.com)
  • Flow cytometry analysis (surface staining) of human peripheral blood cells with anti-human CD20 (LT20) APC. (exbio.cz)
  • The CD20 antigen can also be detected at low levels on a subset of peripheral blood T-cells. (researchhunt.com)
  • a chimeric monoclonal antibody against the CD20 antigen increased survival when it was added to chemotherapy for individuals with systemic CD20+ diffuse large B-cell (DLBCL) non-Hodgkin lymphoma (NHL). (ecologicalsgardens.com)
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. (drugs.com)
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. (drugs.com)
  • Vulnerable patients are more than expected: most of them are pediatric patients or subjects treated with corticosteroid, chemotherapy, antimetabolite treatment, anti-CD20 or they have undergone an organ transplant. (mdpi.com)
  • CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. (exbio.cz)
  • Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen. (pubchase.com)
  • Mice were immunized with extra membrane loop of human CD20 (exCD20) polypeptide. (pubchase.com)
  • To perform this function, DC are capable of capturing antigens, processing them, and presenting them on the cell surface complexed to major histocompatibility (MHC) molecules, for example, human leukocyte antigen- (HLA-) DR. Along with that, context-dependent expression of costimulatory molecules, such as CD80 and CD86, and secretion of cytokines occurs. (hindawi.com)
  • The appearance of DSA were preformed (n=5, anti-human leukocyte antigen class II=3, anti-class I and II=2), de novo (n=4, 15.25±4.72 days after transplantation, anti-class II=1, and anti-class I and II=3) and never (n=6). (lww.com)
  • To assess the linearity of the assay, samples were spiked with high concentrations of human CD20 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. (cusabio.com)
  • The recovery of human CD20 spiked to levels throughout the range of the assay in various matrices was evaluated. (cusabio.com)
  • Immunohistochemical analysis of paraffin-embedded normal human lymph node using CD20 (E7B7T) XP ® Rabbit mAb (Alexa Fluor ® 647 Conjugate) (red) and DAPI #4083 (blue). (cellsignal.cn)
  • The exCD20 antigen showed a desired immune response and was able to develop a monoclonal antibody, 3B4C10, which reacted well with peptide antigen as well as native antigen on the surface of Raji B-cell line. (pubchase.com)
  • The vaccine formulations targeting these antigens have caused a relatively weak immune response. (oncolink.org)
  • This includes the amount of shed antigen in the serum at the time of treatment that could initiate immune complex formation as well as the shedding of inhibitory material into the serum possibly effecting an immune response. (jcancer.org)
  • They are generated by immunizing an animal with an antigen to elicit an immune response. (cellsignal.cn)
  • The monoclonals (mAbs) that we have developed against specific immunogenic tumor membrane proteins have been studied in detail. (jcancer.org)
  • These tumor proteins, when first defined, were referred to as tumor associated antigens. (jcancer.org)
  • Monoclonals that we were able to develop from tumor specific proteins derived from colon and pancreas cancer were found capable of targeting those tumors to induce apoptosis. (jcancer.org)
  • We conclude that the relationship between complement-regulatory proteins CFHR1 and CFHR3 and response to anti-CD20 mAb therapy varies based on the specific anti-CD20 mAb used. (cusabio.com)
  • Clinical studies have indicated that anti-CD20 mAb-based therapies represent an effective treatment for various diseases with overexpression of CD20 on their cell surface, such as non-Hodgkin's lymphoma, hemolytic anemia, as well as autoimmune diseases like rheumatoid arthritis. (pubchase.com)
  • The present invention relates to antigen binding molecules (ABMs). (justia.com)
  • In fact, this type of antigen was the target of the first monoclonal antibody therapy for a malignancy (B-cell lymphoma) in 1982. (oncolink.org)
  • Case Report: primary cutaneous T-cell lymphoma with aberrant CD20 expression. (cusabio.com)
  • However, extremely strong immune responses have been generated using a "boost" to the immune system, provided by viruses that encode antigens similar to the target. (oncolink.org)
  • Taken together, these findings warranted further investigation on NAV‑006 as a next generation anti‑CD20 antibody that could improve the efficacy of parent RTX in NHL patients with high levels of CA125. (spandidos-publications.com)
  • Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency. (thermofisher.com)
  • Cragg MS, Walshe CA, Ivanov AO, Glennie MJ: The biology of CD20 and its potential as a target for mAb therapy. (exbio.cz)